Journal Watch · Journal of Medicinal Chemistry · 2026

Design and Optimization of Lysosome-Targeted β-Galactoside Senolytic Prodrugs: Harnessing the Aromatic Ring of Self-Immolative Linkers.

This work identifies Gal-dMor-Gem as a potent senolytic and highlights a generalizable strategy for developing targeted SA-β-gal-responsive prodrugs.

Liu J, Liu X, Fu H et al.Journal of Medicinal Chemistry3 min readPharma relevance 50/100

DOI: 10.1021/acs.jmedchem.5c01922PMID: 41875331Study type: preclinical (animal / model) study

TL;DR

This work identifies Gal-dMor-Gem as a potent senolytic and highlights a generalizable strategy for developing targeted SA-β-gal-responsive prodrugs.

Key findings

  • In senescent mice, Gal-dMor-Gem (0.5 mg/kg) surpassed SSK1 in restoring body weight, improving biochemical parameters, and reducing SA-β-gal, IL-6, and lamin B1 abnormalities in multiple organs.
  • At 1.0 mg/kg, most markers returned to healthy levels.
  • This work identifies Gal-dMor-Gem as a potent senolytic and highlights a generalizable strategy for developing targeted SA-β-gal-responsive prodrugs.

Numbers at a glance (from the abstract)

3.7-fold

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Its senolytic index reached 16.1-56.7 across six senescent cell (SnC) models, a 2.8- to 3.7-fold improvement over the nontargeted SSK1. Gal-dMor-Gem released Gem faster and preferentially induced SnC apoptosis, as validated in a coculture model. Biodistribution studies confirmed its preferential accumulation and activation in senescent tissues.

Full abstract (original)

Background: To improve senolytic efficacy and selectivity, we designed gemcitabine (Gem)-based galactoside prodrugs activated by senescence-associated β-galactosidase (SA-β-gal), bearing lysosome-targeting groups at the 3- and 5-positions of the self-immolative linker aromatic ring. This strategy avoids stereocenter formation and promotes faster, electron-donating-effect-driven drug release. Gal-dMor-Gem, with two morpholine groups, showed the strongest activity.

What they did: Its senolytic index reached 16.1-56.7 across six senescent cell (SnC) models, a 2.8- to 3.7-fold improvement over the nontargeted SSK1. Gal-dMor-Gem released Gem faster and preferentially induced SnC apoptosis, as validated in a coculture model. Biodistribution studies confirmed its preferential accumulation and activation in senescent tissues.

Results & conclusions: In senescent mice, Gal-dMor-Gem (0.5 mg/kg) surpassed SSK1 in restoring body weight, improving biochemical parameters, and reducing SA-β-gal, IL-6, and lamin B1 abnormalities in multiple organs. At 1.0 mg/kg, most markers returned to healthy levels. This work identifies Gal-dMor-Gem as a potent senolytic and highlights a generalizable strategy for developing targeted SA-β-gal-responsive prodrugs.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c01922 · PubMed 41875331.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Journal of Medicinal Chemistry for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

This work identifies Gal-dMor-Gem as a potent senolytic and highlights a generalizable strategy for developing targeted SA-β-gal-responsive prodrugs.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. Its senolytic index reached 16.1-56.7 across six senescent cell (SnC) models, a 2.8- to 3.7-fold improvement over the nontargeted SSK1.

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.5c01922. PubMed ID: 41875331. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Liu J, Liu X, Fu H et al.. Design and Optimization of Lysosome-Targeted β-Galactoside Senolytic Prodrugs: Harnessing the Aromatic Ring of Self-Immolative Linkers.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.5c01922.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/design-and-optimization-of-lysosome-targeted-galactoside-senolytic-prodr-c01922/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides